JSPR
What one share of Jasper Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (“CSU”), Chronic
Jasper Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.23 |
|---|---|
| Cash and investments | $0.26 |
| Book value | $0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$51.70 | — | −$29.82 | — | — |
| 2021 | — | −$26.89 | — | −$29.56 | — | — |
| 2022 | — | −$10.33 | — | −$12.57 | — | $9.46 |
| 2023 | — | −$6.18 | — | −$4.99 | — | $7.03 |
| 2024 | — | −$4.89 | — | −$4.29 | — | $4.11 |
| 2025 | — | −$3.95 | — | −$4.03 | — | $0.15 |